Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
Regina M MyersBrian T HillBronwen E ShawSoyoung KimHeather R MillardMinoo BattiwallaNavneet S MajhailDavid BuchbinderHillard M LazarusBipin P SavaniMary E D FlowersAnita D SouzaMatthew J EhrhardtAmelia LangstonJean A YaredRobert J HayashiAndrew DalyRichard F OlssonYoshihiro InamotoAdriana K MaloneZachariah DeFilippSteven P MargossianAnne B WarwickSamantha JaglowskiAmer BeitinjanehHenry FungKimberly A KasowDavid I MarksJana ReynoldsKeith Stockerl-GoldsteinBaldeep WirkWilliam A WoodMehdi HamadaniPrakash SatwaniPublished in: Cancer (2017)
Despite generally favorable outcomes, 2-year survivors of auto-HCT for cHL or DLBCL have an excess late-mortality risk in comparison with the general population and experience an assortment of late complications. Cancer 2018;124:816-25. © 2017 American Cancer Society.